Precision Oncology for Metastatic Prostate Cancer: Translation into Practice.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 32863055.
- Also identified by DOI 10.1016/j.eururo.2020.08.021.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
While the principles of precision medicine have been readily embraced by all stakeholders, multiple conceptional and structural challenges hinder its broad implementation in clinical practice. PROfound provides the highest level of evidence for the use of a poly(adenosine diphosphate-ribose) polymerase inhibitor in prostate cancer so far. It is an undoubtedly positive trial, but it also clearly shows the complexity of precision oncology for prostate cancer and the challenges of translating genomics into treatment for metastatic castration-resistant disease.
Medical subject headings
- Medical Oncology
- Precision Medicine
- Prostatic Neoplasms